Table of Contents
Journal of Geriatrics
Volume 2015, Article ID 703425, 7 pages
http://dx.doi.org/10.1155/2015/703425
Research Article

Treating Urge Incontinence in Older Women: A Cost-Effective Investment in Quality-Adjusted Life-Years (QALY)

1Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
2Department of Healthcare Policy and Research, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
3Crozer Chester Medical Center, Upland, PA 19013, USA
4Birmingham/Atlanta Veterans Affairs Geriatric Research, Education, and Clinical Center, Birmingham, AL 35233, USA
5Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA

Received 6 November 2014; Accepted 16 January 2015

Academic Editor: Ian Stuart-Hamilton

Copyright © 2015 Victoria L. Phillips et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. S. Coyne, M. Kvasz, A. M. Ireland, I. Milsom, Z. S. Kopp, and C. R. Chapple, “Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States,” European Urology, vol. 61, pp. 88–95, 2012. View at Publisher · View at Google Scholar
  2. W. F. Stewart, J. B. van Rooyen, G. W. Cundiff et al., “Prevalence and burden of overactive bladder in the United States,” World Journal of Urology, vol. 20, no. 6, pp. 327–336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. K. L. Burgio, D. G. Ives, J. L. Locher, V. C. Arena, and L. H. Kuller, “Treatment seeking for urinary incontinence in older adults,” Journal of the American Geriatrics Society, vol. 42, no. 2, pp. 208–212, 1994. View at Google Scholar · View at Scopus
  4. M. G. Lucas, J. L. H. F. Bosch, F. R. Cruz et al., Guidelines on Urinary Incontinence, European Association of Urology, 2012.
  5. E. A. Gormley, D. J. Lightner, K. L. Burgio et al., Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guidelines, American Urology Association, 2011.
  6. I. Milsom, P. Abrams, L. Cardozo, R. G. Roberts, J. Thüroff, and A. J. Wein, “How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study,” BJU International, vol. 87, no. 9, pp. 760–766, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Novara, A. Galfano, S. Secco et al., “A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder,” European Urology, vol. 54, no. 4, pp. 740–764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Dumoulin and J. Hay-Smith, “Pelvic floor muscle training versus no treatment for urinary incontinence in women. A Cochrane systematic review,” European Journal of Physical and Rehabilitation Medicine, vol. 44, no. 1, pp. 47–63, 2008. View at Google Scholar · View at Scopus
  9. National Institute for Clinical Health and Clinical Excellence, Urinary Incontinence: The Management of Urinary Incontinence in Women, Clinical Guidelines CG40, 2006.
  10. S. Papanicolaou, M. E. Pons, C. Hampel et al., “Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting: examples from three countries participating in the PURE study,” Maturitas, vol. 52, supplement 2, pp. S35–S47, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. K. L. Burgio, J. L. Locher, P. S. Goode et al., “Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial,” The Journal of the American Medical Association, vol. 280, no. 23, pp. 1995–2000, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. K. L. Burgio, P. S. Goode, J. L. Locher et al., “Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial,” Journal of the American Medical Association, vol. 288, no. 18, pp. 2293–2299, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. A. C. Diokno, R. A. Appell, P. K. Sand et al., “Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial,” Mayo Clinic Proceedings, vol. 78, no. 6, pp. 687–695, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Hesch, “Agents for treatment of overactive bladder: a therapeutic class review,” Proceedings (Baylor University. Medical Center), vol. 20, no. 3, pp. 307–314, 2007. View at Google Scholar
  15. W. J. Sieber, E. J. Groessl, K. M. David, T. G. Ganiats, and R. M. Kaplan, Quality of Well Being Self-Administered (QWB-SA) Scale, 2008.
  16. M. Tzefos, C. Dolder, and J. L. Olin, “Fesoterodine for the treatment of overactive bladder,” Annals of Pharmacotherapy, vol. 43, no. 12, pp. 1992–2000, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Hakkaart, P. Verboom, R. Phillips, and M. J. Al, “The cost utility of solifenacin in the treatment of overactive bladder,” International Urology and Nephrology, vol. 41, no. 2, pp. 293–298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Ko, D. C. Malone, and E. P. Armstrong, “Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder,” Pharmacotherapy, vol. 26, no. 12, pp. 1694–1702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R.-H. Bödeker, H. Madersbacher, C. Neumeister, and M. Zellner, “Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence,” BMC Urology, vol. 10, article 15, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Chughtai, R. Levin, and E. De, “Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin,” Clinical Interventions in Aging, vol. 3, no. 3, pp. 503–509, 2008. View at Google Scholar · View at Scopus
  21. K. L. Burgio, J. L. Locher, and P. S. Goode, “Combined behavioral and drug therapy for urge incontinence in older women,” Journal of the American Geriatrics Society, vol. 48, no. 4, pp. 370–374, 2000. View at Google Scholar · View at Scopus
  22. Consumers Union, Evaluating Prescription Drugs Used to Treat: Overactive Bladder Comparing Effectiveness, Safety, and Price, 2010.
  23. R. U. Anderson, D. Mobley, B. Blank, D. Saltzstein, J. Susset, and J. S. Brown, “Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group,” The Journal of Urology, vol. 161, no. 6, pp. 1809–1812, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. N. R. Zinner, A. Mattiasson, and S. L. Stanton, “Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients,” Journal of the American Geriatrics Society, vol. 50, no. 5, pp. 799–807, 2002. View at Publisher · View at Google Scholar
  25. S. Lee, B. Malhotra, D. Creanga, M. Carlsson, and P. Glue, “A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder,” BMC Medical Research Methodology, vol. 9, article 55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. A. Appell, P. Sand, R. Dmochowski, R. Anderson, and N. Zinner, “Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study,” Mayo Clinic Proceedings, vol. 76, no. 4, pp. 358–363, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Siami, L. S. Seidman, and D. Lama, “A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT),” Clinical Therapeutics, vol. 24, no. 4, pp. 616–628, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. L. Tunis, M. E. Minshall, M. St. Charles, B. J. Pandya, and R. W. Baran, “Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US,” Current Medical Research and Opinion, vol. 24, no. 11, pp. 3085–3096, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. C. Haddix, S. M. Teutsch, and P. S. Corso, Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation, Oxford University Press, Oxford, UK, 2nd edition, 2003.